About Acidic leucine-rich nuclear phosphoprotein 32 family member B
Acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B) is a protein
from Homo sapiens identified by UniProt accession
Q92688, 251 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | Acidic leucine-rich nuclear phosphoprotein 32 family member B |
|---|
| UniProt accession | Q92688 |
|---|
| Gene | ANP32B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 251 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (68)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- mean corpuscular volume · score 0.40
- erythrocyte count · score 0.39
- mean corpuscular hemoglobin · score 0.38
- mean corpuscular hemoglobin concentration · score 0.35
- eosinophil count · score 0.33
- red blood cell density measurement · score 0.33
- primary biliary cirrhosis · score 0.32
- Immature Reticulocyte Fraction Measurement · score 0.29
- Red cell distribution width · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92688-F1 | alphafold | PREDICTED | 78.98 | — |
Amino-acid sequence (251 residues)
MDMKRRIHLE LRNRTPAAVR ELVLDNCKSN DGKIEGLTAE FVNLEFLSLI NVGLISVSNL PKLPKLKKLE LSENRIFGGL DMLAEKLPNL THLNLSGNKL KDISTLEPLK KLECLKSLDL FNCEVTNLND YRESVFKLLP QLTYLDGYDR EDQEAPDSDA EVDGVDEEEE DEEGEDEEDE DDEDGEEEEF DEEDDEDEDV EGDEDDDEVS EEEEEFGLDE EDEDEDEDEE EEEGGKGEKR KRETDDEGED D
Explore Acidic leucine-rich nuclear phosphoprotein 32 family member B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets